Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Roche Holding AG | 293 |
| 2 | Becton Dickinson and Co | 242 |
| 3 | University of California | 188 |
| 4 | 10X Genomics Inc | 174 |
| 5 | Regeneron Pharmaceuticals Inc | 158 |
| 6 | Leland Stanford Junior University | 150 |
| 7 | Harvard University | 146 |
| 8 | Massachusetts Institute of Technology | 140 |
| 9 | Amgen Inc | 134 |
| 10 | Institut National de la Santé et de la Recherche Médicale | 120 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 7,074 |
| 2 | A61P | Therapeutic activity (drug indications) | 6,093 |
| 3 | C07K | Peptides | 5,065 |
| 4 | C12N | Microorganisms, enzymes | 4,019 |
| 5 | G01N | Investigating / analysing materials | 3,558 |
| 6 | C12Q | Measuring/testing involving enzymes | 3,030 |
| 7 | Y02A | Climate change adaptation | 1,067 |
| 8 | C07D | Heterocyclic compounds | 614 |
| 9 | C12Y | Enzyme nomenclature (EC numbers) | 448 |
| 10 | B01L | 303 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionRepresentative patents
The filings that best characterise the patent activity around this compound, most-referenced first.
| Title | Year | Assignee |
|---|---|---|
| CY5.5 carboxylic acid marked heat shock protein 90-II type fluorescent probe, preparation method and application thereof | 2025 | |
| Heat shock protein 90-I type fluorescent probe coupled with CY5.5 carboxylic acid, preparation method and application thereof | 2025 |
How research activity has moved
Papers published per year for this compound, over the last decade of indexed records.
| Year | Papers |
|---|---|
| 2016 | 24 |
| 2017 | 15 |
| 2018 | 22 |
| 2019 | 21 |
| 2020 | 12 |
| 2021 | 9 |
| 2022 | 12 |
| 2023 | 10 |
| 2024 | 12 |
| 2025 | 2 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Michael Schäfers | University of Münster | 10 |
| 2 | Ralph Weissleder | Massachusetts General Hospital | 10 |
| 3 | Christoph Bremer | University Hospital Münster | 9 |
| 4 | Carsten Höltke | University Hospital Münster | 7 |
| 5 | Alexei Bogdanov | Massachusetts General Hospital | 7 |
| 6 | Kwangmeyung Kim | Korea Institute of Science and Technology | 7 |
| 7 | Walter Heindel | University Hospital Münster | 6 |
| 8 | Zdravka Medarova | Massachusetts General Hospital | 6 |
| 9 | Eyk Schellenberger | Harvard University | 6 |
| 10 | Sanjiv S. Gambhir | Stanford University | 6 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. | 2003 | 549 | Nanoplatforms for cancer theranostics |
| Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci | 2007 | 421 | Angiogenesis and VEGF in Cancer |
| Tumor-homing multifunctional nanoparticles for cancer theragnosis: Simultaneous diagnosis, drug delivery, and therapeutic monitoring | 2010 | 350 | Nanoparticle-Based Drug Delivery |
| Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V–Cy5.5 conjugate | 2004 | 348 | Nanoplatforms for cancer theranostics |
| In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts | 2004 | 347 | Immunotherapy and Immune Responses |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of Cy5.5?
Which organizations hold the most patents related to Cy5.5?
What are the most active research areas in Cy5.5 patents based on CPC classification?
What notable applications of Cy5.5 are documented in the literature?
Who are the most prolific researchers publishing on Cy5.5?